|
Adjuvant Trastuzumab: Select publications |
Dang C et al. Updated cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/ amplified breast cancer (BCA). Proc ASCO 2006;Abstract 582.
HERA Study Team. Trastuzumab (H: Herceptin) following adjuvant chemotherapy (CT) significantly improves disease-free survival (DFS) in early breast cancer (BC) with HER2 overexpression: The HERA Trial. San Antonio
Breast Cancer Symposium 2005;Abstract 11.
Joensuu H et al; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20. Abstract
Kim C et al. Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo. San Antonio Breast
Cancer Symposium 2005;Abstract 46.
Perez EA et al. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial. Proc ASCO 2005;Abstract 556.
Piccart-Gebhart MJ. First results of the HERA trial. Presentation. ASCO 2005. No abstract available
Piccart-Gebhart MJ et al; Herceptin Adjuvant
(HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659-72. Abstract
Press MF et al. Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracycline-containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumab (herceptin) in the adjuvant setting. San Antonio Breast Cancer
Symposium 2005;Abstract 1045.
Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-
84. Abstract
Romond EH et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer — Combined analysis of NSABP-B31/ NCCTG-N9831. Presentation. ASCO 2005. No
abstract available
Tan-Chiu E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23(31):7811-9. Abstract
|